{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:00:10Z","timestamp":1792800010048,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"DOI":"10.1038\/s41371-026-01227-5","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T17:15:50Z","timestamp":1789406150000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hypertensive heart disease\u00a0and HFpEF:atrial functional valve regurgitation as the trigger of acute heart failure in a syndrome of exertional dyspnoea"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0625-7555","authenticated-orcid":false,"given":"Maria Giulia","family":"Bellicini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"1227_CR1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic HF. Eur Heart J. 2021;42:3599\u2013726.","journal-title":"Eur Heart J"},{"key":"1227_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1001\/jama.1996.03530440037034","volume":"275","author":"D Levy","year":"1996","unstructured":"Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive HF. JAMA. 1996;275:20.","journal-title":"JAMA"},{"key":"1227_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/eurjpc\/zwad344","volume":"31","author":"PK Baffour","year":"2024","unstructured":"Baffour PK, Jahangiry L, Jain S, Sen A, Aune D. Blood pressure, hypertension, andtherisk ofHF:asystematicreviewandmeta-analysis of cohort studies. Eur J Prev Cardiol. 2024;31:529\u201356.","journal-title":"Eur J Prev Cardiol"},{"key":"1227_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/eurheartj\/ehaf524","volume":"47","author":"A Peikert","year":"2026","unstructured":"Peikert A, Fontana M, Solom S, Thum T. Left ventricular hypertrophy and myocardial fibrosis in heartfailure with preserved ejectionfraction: mechanisms and treatment. Eur Heart J. 2026;47:37\u201353.","journal-title":"Eur Heart J"},{"key":"1227_CR5","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1161\/HYPERTENSIONAHA.123.21708","volume":"81","author":"A Gonz\u00e1lez","year":"2024","unstructured":"Gonz\u00e1lez A, L\u00f3pez B, Ravassa S, San Jos\u00e9 G, Latasa I, Butler J, et al. Myocardial interstitial fibrosis in hypertensive heart disease: from mechanisms to clinical management. Hypertension. 2024;81:e28\u2013e42. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.123.21708","journal-title":"Hypertension"},{"key":"1227_CR6","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1161\/01.RES.10.3.250","volume":"10","author":"FZ Meerson","year":"1962","unstructured":"Meerson FZ. Compensatory hyperfunction of the heart and cardiac insufficiency. Circ Res. 1962;10:250\u20138.","journal-title":"Circ Res"},{"key":"1227_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0002-9149(75)90005-3","volume":"35","author":"E Rapaport","year":"1975","unstructured":"Rapaport E. Natural history of aortic and mitral valve disease. Am J Cardiol. 1975;35:221\u20137.","journal-title":"Am J Cardiol"},{"key":"1227_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0002-9149(87)90998-2","volume":"60","author":"P Spirito","year":"1987","unstructured":"Spirito P, Maron BJ, Bonow RO, Epstein SE. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol. 1987;60:123\u20139.","journal-title":"Am J Cardiol"},{"key":"1227_CR9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.amjcard.2003.09.050","volume":"93","author":"JE Rame","year":"2004","unstructured":"Rame JE, Ramilo M, Spencer N, Blewett C, Mehta SK, Dries DL, et al. Development of a depressed left ventricular ejection fraction in patients with left ventricular hypertrophy and a normal ejection frac tion. Am J Cardiol. 2004;93:234\u20137.","journal-title":"Am J Cardiol"},{"key":"1227_CR10","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1016\/j.jacc.2003.11.064","volume":"43","author":"MH Drazner","year":"2004","unstructured":"Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol. 2004;43:2207\u201315.","journal-title":"J Am Coll Cardiol"},{"key":"1227_CR11","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1093\/eurheartj\/ehag175","volume":"47","author":"I Landsteiner","year":"2026","unstructured":"Landsteiner I, Verwerft J, Belov D, Verbrugge FH, Lewis GD. Heart failure with preserved ejection fraction: pathophysiology, clinical assessment, and management of exercise intolerance. Eur Heart J. 2026;47:3065\u2013101. https:\/\/doi.org\/10.1093\/eurheartj\/ehag175","journal-title":"Eur Heart J"},{"key":"1227_CR12","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/ehjci\/jeae178","volume":"25","author":"CI Ottosen","year":"2024","unstructured":"Ottosen CI, Nadruz W, Inciardi RN, Johansen ND, Fudim M, Biering Srensen T. Diastolic dysfunction in hypertension: a comprehensive review of pathophysiology, diagnosis, and treatment. Eur Heart J Cardiovasc Imaging. 2024;25:1525\u201336.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1227_CR13","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.echo.2025.03.011","volume":"38","author":"SF Nagueh","year":"2025","unstructured":"Nagueh SF, Sanborn DY, Anderson B, Billick K, Derumeaux G, Klein A, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography and for heart failure with preserved ejection fraction diagnosis: an update from the American Society of Echocardiography. J Am Soc Echocardiogr. 2025;38:537\u201369.","journal-title":"J Am Soc Echocardiogr"},{"key":"1227_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2025.1678712","volume":"12","author":"MG Bellicini","year":"2025","unstructured":"Bellicini MG. Systolic pulmonary artery pressure threshold to define pulmonary and peripheral congestion in acute heart failure in absence of severe tricuspid regurgitation. Front Cardiovasc Med. 2025;12:1678712.","journal-title":"Front Cardiovasc Med"},{"key":"1227_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jacc.2008.08.064","volume":"53","author":"A Rudolph","year":"2009","unstructured":"Rudolph A, Abdel-Aty H, Bohl S, Boye P, Zagrosek A, Dietz R, et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy. J Am Coll Cardiol. 2009;53:3.","journal-title":"J Am Coll Cardiol"},{"key":"1227_CR16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3390\/diagnostics13010137","volume":"13","author":"M Zdravkovic","year":"2023","unstructured":"Zdravkovic M, Klasnja S, Popovic M, Djuran P, Mrda D, Ivankovic T, et al. Cardiacmagnetic resonance in hypertensive heart disease: time for a new chapter. Diagnostics. 2023;13:137.","journal-title":"Diagnostics"},{"key":"1227_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11906-019-0910-6","volume":"21","author":"CL Schumann","year":"2019","unstructured":"Schumann CL, Jaeger NR, Kramer CM. Recent advances in imaging of hypertensive heart disease. Curr Hypertens Rep. 2019;21:3.","journal-title":"Curr Hypertens Rep"},{"key":"1227_CR18","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12968-015-0176-3","volume":"17","author":"TA Treibel","year":"2015","unstructured":"Treibel TA, Zemrak F, Sado DM, Banypersad MS, White SK, Maestrini V, et al. Extracellular volume quantification in isolated hypertension changes at the detectable limits? J Cardiovasc Magn Reson. 2015;17:74.","journal-title":"J Cardiovasc Magn Reson"},{"key":"1227_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/ncpcardio0158","volume":"2","author":"J D\u0131ez","year":"2005","unstructured":"D\u0131ez J, Gonzalez A, Lopez B, Querejeta R. Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. Nat Clin Pract Cardiovasc Med. 2005;2:209\u201316.","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"1227_CR20","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.5646\/ch.2026.32.e14","volume":"32","author":"P Lertsiripatarajit","year":"2026","unstructured":"Lertsiripatarajit P, Wanitchung K, Prechawuttidech S, Tongsai S, Kaolawanich Y, et al. Cardiac magnetic resonance assessment of left ventricular phenotypes and prognostic implications in hypertensive heart disease. Clin Hypertens. 2026;32:e14 https:\/\/doi.org\/10.5646\/ch.2026.32.e14","journal-title":"Clin Hypertens"},{"key":"1227_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-79729-6","volume":"10","author":"P Garg","year":"2020","unstructured":"Garg P, Assadi H, Jones R, Chan WB, Metherall P, Thomas R, et al. Left ventricular fibrosis and hypertrophy are associated with mortality in heart failure with preserved ejection fraction. Sci Rep. 2020;10:20363 https:\/\/doi.org\/10.1038\/s41598-020-79729-6","journal-title":"Sci Rep"},{"key":"1227_CR22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Pfeffer MS, Swedberg K, Granger CB, Held P, McMurray JJV, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Tri al. Lancet. 2003;362:777\u201381.","journal-title":"Lancet"},{"key":"1227_CR23","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","volume":"359","author":"BM Massie","year":"2008","unstructured":"Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456\u201367.","journal-title":"N Engl J Med"},{"key":"1227_CR24","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactonefor heartfailure withpreservedejectionfraction. N Engl J Med. 2014;370:1383\u201392.","journal-title":"N Engl J Med"},{"key":"1227_CR25","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, John JV, McMurray JJV, Inder S, Anand IS, Junbo Ge DP, et al. Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609\u201320.","journal-title":"N Engl J Med"},{"key":"1227_CR26","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089\u201398.","journal-title":"N Engl J Med"},{"key":"1227_CR27","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451\u201361.","journal-title":"N Engl J Med"},{"key":"1227_CR28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jchf.2017.04.012","volume":"5","author":"FH Messerli","year":"2017","unstructured":"Messerli FH, Rimoldi SF, Bangalore S. The transition from hypertension to heart failure contemporary update. JACC Heart Fail. 2017;5:543\u201351.","journal-title":"JACC Heart Fail"},{"key":"1227_CR29","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.amjcard.2004.12.032","volume":"95","author":"JL Januzzi","year":"2005","unstructured":"Januzzi JL, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95:948\u201354.","journal-title":"Am J Cardiol"},{"key":"1227_CR30","doi-asserted-by":"publisher","first-page":"100054","DOI":"10.1016\/j.ijcahf.2025.100054","volume":"1","author":"MG Bellicini","year":"2025","unstructured":"Bellicini MG. HFpEF and HFmrEF in acute heart failure: isolated diastolic dysfunction or alternative cardiac pathologies? Int J Cardiol Acute Heart Fail. 2025;1:100054 https:\/\/doi.org\/10.1016\/j.ijcahf.2025.100054","journal-title":"Int J Cardiol Acute Heart Fail"},{"key":"1227_CR31","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","volume":"8","author":"VS Hahn","year":"2020","unstructured":"Hahn VS, Yanek LR, Vaishnav J, Ying W, Vaidya D, Lee YZJ, et al. Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis. JACC Heart Fail. 2020;8:712\u201324. https:\/\/doi.org\/10.1016\/j.jchf.2020.04.007","journal-title":"JACC Heart Fail"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01227-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01227-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01227-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T17:15:51Z","timestamp":1789406151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01227-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":31,"alternative-id":["1227"],"URL":"https:\/\/doi.org\/10.1038\/s41371-026-01227-5","relation":{},"ISSN":["1476-5527"],"issn-type":[{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"12 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}